{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:41:32Z","timestamp":1781617292725,"version":"3.54.5"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH\/NCATS","award":["# 2UL1-TR-2384"],"award-info":[{"award-number":["# 2UL1-TR-2384"]}]},{"name":"Clinical and Translational Science Center at Weill Cornell Medical College"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine whether rheumatologists and pulmonologists have distinct disciplinary approaches to the management of systemic autoimmune rheumatic disease (SARD)-interstitial lung disease (ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a cross-sectional survey study of US rheumatologists and pulmonologists. Surveys were electronically distributed to physicians identified through professional societies and social media. Surveys contained case questions on SARD-ILD management for patients with mixed connective tissue disease, idiopathic inflammatory myopathy, rheumatoid arthritis, systemic sclerosis and Sjogren\u2019s with varying ILD severity (asymptomatic, symptomatic, progressive). Respondents also answered questions on treatment decision-making, comfort with pharmacologic modalities and opinions about interdisciplinary co-management. We analyzed responses submitted 5\u20139\/2024. We compared specialists\u2019 responses via univariate logistic regression, Chi-squared or Fisher\u2019s exact tests; we performed multivariable logistic regression of case questions controlling for practice setting, clinical experience and geographic region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analyses included 309 participants (rheumatologists\u2009=\u2009184, pulmonologists\u2009=\u2009125). Compared with pulmonologists, rheumatologists were less likely to treat asymptomatic and symptomatic ILD with corticosteroids for all SARD except asymptomatic systemic sclerosis (odds ratios [OR] 0.14\u20130.45), and to treat progressive ILD with antifibrotics (OR 0.26\u20130.30). Conversely, rheumatologists were more likely than pulmonologists to either add or modify immunomodulation\/immunosuppression for all symptomatic and progressive SARD-ILD (OR 1.82\u20135.44). There were disciplinary differences in the relative importance of clinical variables to treatment approaches. Specialists reported ownership over different domains of treatment decision-making and healthcare maintenance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This national study suggests distinct disciplinary approaches to management of SARD-ILD, and highlights opportunities to leverage complementary expertise through a co-management paradigm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkag050","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:50:21Z","timestamp":1776430221000},"source":"Crossref","is-referenced-by-count":1,"title":["Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-2752","authenticated-orcid":false,"given":"Genna","family":"Braverman","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Hospital for Special Surgery , New York, NY,","place":["USA"]},{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5587-5427","authenticated-orcid":false,"given":"Kerri I","family":"Aronson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine, Weill Cornell Medicine , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2911-6800","authenticated-orcid":false,"given":"Robert","family":"Spiera","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Hospital for Special Surgery , New York, NY,","place":["USA"]},{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026050522013559200_rkag050-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2017.04.002","article-title":"Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease","volume":"127","author":"Natalini","year":"2017","journal-title":"Respir Med"},{"key":"2026050522013559200_rkag050-B2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026050522013559200_rkag050-B3","first-page":"67","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)","volume":"85","author":"Antoniou","year":"2026","journal-title":"Eur Respir J"},{"key":"2026050522013559200_rkag050-B4","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/acr.25347","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026050522013559200_rkag050-B5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026050522013559200_rkag050-B6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/rheumatology\/keab552","article-title":"The attitudes and practices of physicians caring for patients with rheumatoid arthritis-associated interstitial lung disease: an international survey","volume":"61","author":"Solomon","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026050522013559200_rkag050-B7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026050522013559200_rkag050-B8","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026050522013559200_rkag050-B9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026050522013559200_rkag050-B10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2026050522013559200_rkag050-B11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050522013559200_rkag050-B12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2026050522013559200_rkag050-B13","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026050522013559200_rkag050-B14","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2026050522013559200_rkag050-B15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026050522013559200_rkag050-B16","doi-asserted-by":"crossref","first-page":"103463","DOI":"10.1016\/j.autrev.2023.103463","article-title":"Should we use nintedanib as early therapy in patients with SSc-ILD?","volume":"23","author":"Zanatta","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2026050522013559200_rkag050-B17","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026050522013559200_rkag050-B18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.chest.2023.02.027","article-title":"Disparities in antifibrotic medication utilization among veterans with idiopathic pulmonary fibrosis","volume":"164","author":"Kaul","year":"2023","journal-title":"Chest"},{"key":"2026050522013559200_rkag050-B19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1513\/AnnalsATS.202007-901OC","article-title":"Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis","volume":"18","author":"Dempsey","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2026050522013559200_rkag050-B20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1513\/AnnalsATS.202308-697RL","article-title":"Uptake of antifibrotics for patients with idiopathic pulmonary fibrosis: 2016\u20132022","volume":"21","author":"Shankar","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026050522013559200_rkag050-B21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12890-021-01811-0","article-title":"Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States","volume":"22","author":"Dempsey","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026050522013559200_rkag050-B22","author":"Active Physicians by Age and Specialty, 2021","year":"2021"},{"key":"2026050522013559200_rkag050-B23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026050522013559200_rkag050-B24","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"2026050522013559200_rkag050-B25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026050522013559200_rkag050-B26","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1093\/rheumatology\/keaf200","article-title":"Real-world care patterns and specialist encounters of patients with systemic autoimmune rheumatic disease-related interstitial lung disease in the United States: a retrospective administrative claims database analysis","volume":"64","author":"Yang","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026050522013559200_rkag050-B27","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2665-9913(24)00082-1","article-title":"Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study","volume":"6","author":"Hollick","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026050522013559200_rkag050-B28","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1093\/rheumatology\/keaf240","article-title":"The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis","volume":"64","author":"Biddle","year":"2025","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkag050\/68133677\/rkag050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/2\/rkag050\/68133677\/rkag050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/2\/rkag050\/68133677\/rkag050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:01:46Z","timestamp":1778032906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag050\/8660665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag050","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag050"}}